[PDF] Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. | Semantic Scholar (2024)

Ceftaroline exhibited promising high potency and wide coverage against Gram-positive and -negative pathogens known to cause CAP, especially isolates of MDR pneumococci and methicillin-resistant S. aureus.

Cefaroline plus amikacin appeared as the most likely synergistic combination against resistant gram-negative pathogens and represents a promising therapeutic option, and further studies are warranted to elucidate the clinical value of ceftaroline combinations againstresistant gram- negative pathogens.

Data support the use of ceftaroline fosamil at doses of 600 mg q12h to treat S. aureus strains with MICs of ≤2 μg/ml, and an fTMIC of 25 to 30% would make a suitable pharmacodynamic index target, but f TMIC values of ≥50% are needed to suppress the emergence of resistance and require clinical evaluation.

Ceftaroline surveillance in the United States during 2008-2010 documented sustained potency and spectrum against multidrug-resistant S. aureus and multidrog- resistant S. pneumoniae known to cause ABSSSI and CABP.

Ceftaroline has excellent in vitro activity against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), which makes it an attractive monotherapy, but it lacks activity against problem gram-negative bacteria (eg, Pseudomonas spp.), which will likely limit its use for serious health care-associated infections.

CLSI broth microdilution was used and test conditions were modified to determine effects of CEM-101 activity and simultaneous changes in the pH and protein were tested.

The spectrum of activity of ceftaroline was evaluated against 1,247 bacterial isolates representing 44 different species or phenotypic groups and for the majority of species, the activity was comparable or superior to that of Ceftriaxone.

...

...

S-3578 exhibited a broad antibacterial spectrum and, particularly, had excellent activity against gram-positive bacteria including methicillin-resistant staphylococci and PRSP, which was comparable to that of ceftriaxone.

PI-0903M demonstrated broader in vitro activity against gram-positive bacteria, particularly against multidrug-resistant staphylococci and streptococci of current clinical concern, than currently available extended-spectrum cephalosporins while maintaining similar activity against Gram-negative pathogens.

The novel cephalosporin was 8- to 16-fold more potent than ceftriaxone, cefepime, or amoxicillin-clavulanate against both penicillin-intermediate and -resistant S. pneumoniae and was highly active against gram-positive bacteria, particularly against multidrug-resistant staphylococci and streptococci.

This survey of the susceptibilities of more than 1,000 multidrug-resistant gram- positive isolates to RWJ-54428 indicates that this new cephalosporin has the potential to be useful in the treatment of infections due to gram-positive bacteria, including strains resistant to currently available antimicrobials.

BAL9141 demonstrated excellent activity against many tested pathogens displaying various resistance phenotypes, and should be particularly valuable in the treatment of MRSA as well as for drug-resistant streptococci, while maintaining a spectrum resembling a 'third-generation' cephalosporin against other clinically important species.

The usefulness of TAK-599 in the treatment of MRSA infections in humans is suggested, as it showed more rapid and distinct decrease of viable cells of two MRSA strains than did vancomycin and linezolid in vitro.

This well-respected reference continues to serve as the sole major publication providing step-by-step descriptions that enable clinical microbiologists and their staffs to perform all analyses and their control from the receipt of the specimen to the final report.

...

...